On September 22, 2025, IceCure Medical Ltd. announced its participation at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting, held from September 13-17, 2025, in Barcelona, Spain. The company hosted a large number of medical practitioners interested in ProSense® at its booth, offering live demonstrations and information on its single-cryoprobe liquid nitrogen-based cryoablation technology.
Five Key Opinion Leaders presented positive clinical results from four independent studies using ProSense® cryoablation, including three on breast cancer and one on abdominal wall endometriosis. Notably, a study from Institut Curie Hospital found ProSense® to be a safe and effective alternative to surgery for elderly patients with small HR+/Her2- breast cancers. Another study reported significant pain reduction for abdominal wall endometriosis, with pain scores declining from a median of 8 to 1.
Three hands-on training sessions for doctors interested in using ProSense® were very well attended, indicating growing interest from interventional radiologists in expanding their practice to include breast care. IceCure's CEO, Eyal Shamir, emphasized that ProSense® offers the most advanced clinically proven LN2 cryoablation system, and the active sharing of positive findings from investigator-initiated studies at such conferences is crucial for driving adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.